abstract: Flaviviruses (FVs) are among the most medically important arboviruses of the world with the Dengue virus (DENV) accounting for a large percentage of infections observed in tropical and subtropical regions of the world. Globalization, travel, and the expanding range of mosquito vectors, such as Aedes aegypti, have increased the potential of infection rates and illnesses associated with FVs. The DENV and the Zika (ZIKV) FVs frequently co-circulate and generally cause mild self-liming febrile illnesses. However, a secondary infection with a heterologous DENV serotype may lead to life threatening dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). DHF/DSS have been linked to antibody dependent enhancement of infection (ADE), a phenomenon that occurs when antibodies (Abs) formed against an initial infection with one serotype of DENV cross-reacts but does not neutralize a heterologous DENV serotype in a secondary infection. Furthermore, Abs raised against the ZIKV have been observed to cross-react with the DENV and vice versa, which can potentially cause ADE and lead to severe DENV disease. The ZIKV can be transmitted vertically and has been linked to devastating congenital defects such as microcephaly in newborns. FDA approved treatments do not exist for DENV and ZIKV illnesses. Thus, there is a need for safe and effective treatments for these co-circulating viruses. Here, a tetravalent bispecific antibody (bsAb) targeting the ZIKV and all four serotypes of the DENV was expressed in the Nicotiana benthamiana (N. benthamiana) plant. Functional assays of the DENV/ZIKV bsAb demonstrated binding, neutralization, and a significant reduction in ADE activity against both the DENV and the ZIKV. A single chain variable fragment (scFv) and a diabody based on an antibody directed against the immune checkpoint inhibitor PD-L1, were also expressed in N. benthamiana leaves. The smaller sizes of the scFv and diabody confers them with the ability to penetrate deeper tissues making them beneficial in diagnostics, imaging, and possibly cancer therapy. The past few decades has seen long strives in recombinant protein production in plants with significant improvements in production, safety, and efficacy. These characteristics make plants an attractive platform for the production of recombinant proteins, biologics, and therapeutics. / Dissertation/Thesis / Doctoral Dissertation Molecular and Cellular Biology 2019

No description available.

Les furocoumarines constituent l'une des classes de métabolites secondaires dérivant de la voie de biosynthèse des phénylpropanoïdes. Elles ont été décrites comme étant des phytoaléxines mais sont également très largement utilisées par l'Homme pour leurs propriétés thérapeutiques. Un certain nombre d'études biochimiques ont été réalisées afin d'en comprendre la biosynthèse mais peu de choses sont connues concernant leur déterminisme moléculaire. Dans cette étude, nous nous sommes concentrés sur la caractérisation fonctionnelle de gènes appartenant aux prényltransférases aromatiques potentiellement impliquées dans cette voie de biosynthèse. Les prényltransférases catalysent la première étape de la voie de biosynthèse des furocoumarines linéaires ou angulaires. Elles permettent l'addition d'un groupement dimethylally pyrophosphate (DMAPP) sur l'umbelliférone. En utilisant SfN8DT-1, une prényltransférase aromatique récemment caractérisée, comme sonde, nous avons identifié 7 gènes candidats chez deux familles de plantes (Rutaceae et Apiaceae). Dans la mesure où il a été décrit que ces enzymes étaient des protéines membranaires, nous avons adapté un système d'expression hétérologue basé sur l'utilisation de N. benthamiana. Ce système a été validé par l'expression de deux protéines membranaires : un cytochrome P450 CYP98A22 et une prényltransférase déjà caractérisée SfN8DT-1. Nous avons ensuite utilisé ce système d'expression pour réaliser l'étude des 7 gènes nouvellement isolés. Ces travaux nous ont permis de caractériser la première umbelliferone prenyltransferase de Petroselinum crispum capable de catalyser in vitro et in vivo la prénylation du carbone 6 ou 8 de l'umbelliférone en présence de DMAPP permettant ainsi la synthèse respectivement de demethylsuberosin et d'osthenol. Par ailleurs, une étude réalisée in planta chez le persil a permis de mettre en évidence une relation positive entre le niveau d'expression du gène et la teneur en umbelliférone prénylée. L'étude de la surexpression du gène chez Ruta graveolens a permis de mettre en évidence un lien entre l'expression du gène et la disparition de l'umbelliférone. Enfin nous avons identifié la même activité pour une prényltransférase de Pastinaca sativa, ce qui nous amène à émettre l'hypothèse que l'étape de prénylation n'est pas une étape limitante dans la biosynthèse des furocoumarines angulaires, étant donné que le persil ne produit que des furocoumarines linéaires, tandis que le panais produit des furocoumarines linéaires et angulaires. L'utilisation de ces mêmes systèmes d'expression hétérologue de N. benthamiana et R. graveolens nous a également permis d'identifier une seconde prényltransférase aromatique capable de catalyser l'addition de géranylpyrophosphate (GPP) sur l'umbelliférone et sur l'esculétine / Furanocoumarins constitute one of the classes of secondary metabolites deriving from the phenylpropanoid biosynthetic pathway. These molecules are described as phytoalexins in plants but are also used by humans for their pharmaceutical properties. A large number of biochemical studies were carried out to understand their biosynthetic pathway but little information was available concerning the genes involved in the pathway. In this study, we focused on the characterization of genes encoding for aromatic prenyltransferases which were described to be involved in this pathway. Prenlyltransferases catalyze the entry step to the linear or angular furanocoumarin pathway. Hence they catalyze the addition of a dimethylallyl pyrophosphate (DMAPP) prenyl moiety to umbelliferone. Using a recently characterized aromatic prenyltransferase (SfN8DT-1) as a probe, we isolated 7 different candidate genes from two plant families (Rutaceae and Apiaceae). As these enzymes were described as membrane bound proteins, we adapted a heterologous expression system made up of Nicotiana benthamian aand we validated its efficiency by using two membrane-associated enzymes: a cytochrome P450 (CYP98A22) and the already described prenyltransferase SfN8DT-1. Subsequently, this system was used to perform the functional characterization of the 7 newly identified proteins. This way we succeeded to characterize the first umbelliferone prenyltransferase of Petroselinum crispum that was able to catalyze both the 6-C and 8-C prenylation of umbelliferone with DMAPP producing demethylsuberosin and osthenol respectively. We made evidence that these reactions occurred both in vitro and in vivo. In addition, in planta studies performed in P.crispum showed a positive relationship between the gene expression level and the content of prenylated umbelliferone. The overexpression of this gene was investigated in Ruta graveolens and we could provide evidences of a link between the enzymatic activity and the disappearance of umbelliferone. We also reported a similar activity for a prenyltransferase isolated from Pastinaca sativa, which makes us assume that the prenylation step is not a rate limiting step in the biosynthetic pathway of angular furanocoumarins since parsley is producing only linear furanocoumarins whereas parsnip is producing both linear and angular furanocoumarins. In addition, using the same N. benthamiana and R. graveolens heterologous expression systems, we identified a second aromatic prenyltransferase able to catalyze the addition of geranyl pyrophosphate (GPP) both to umbelliferone and esculetin

Os primeiros vasos sanguíneos do embrião de vertebrados, formados de novo a partir de células originadas da mesoderme, originam os vasos linfáticos em um processo denominado vasculogênese. Já no adulto, novos vasos são formados principalmente através da angiogênese (ou linfoangiogênese) a partir da vasculatura pré-existente. Em indivíduos saudáveis, a arquitetura vascular é relativamente estática, sendo que o excesso ou a insuficiência de vasos são comumente relacionados à angiogênese patológica, vinculada a diversas doenças, como câncer, degeneração macular relacionada à idade, isquemia de membros e muitas outras. Dessa forma, o controle local da densidade de vasos sanguíneos torna-se interessante para o tratamento de condições patológicas visando melhoria de prognóstico e cura. Dentre os diversos fatores de crescimento conhecidos, o fator de crescimento endotelial vascular, VEGF, destaca-se como o principal regulador do processo de angiogênese através de isoformas pró-angiogênicas (VEGFxxx) e antiangiogênicas (VEGFxxxb) do gene VEGF-A. Consequentemente, as proteínas codificadas por esse gene constituem um alvo com alto potencial terapêutico. No presente estudo, propusemos a produção das isoformas proteicas recombinantes rhVEGF165, rhVEGF165b e rhVEGF121, oriundas do gene VEGF-A humano, visando à geração de biofármacos que podem ser utilizados para terapia molecular e engenharia tecidual. As sequências codificadoras das isoformas rhVEGF165 e rhVEGF121 foram amplificadas a partir do cDNA total sintetizado de amostras de RNA total de pulmão humano, enquanto que a da isoforma rhVEGF165b foi gerada através da mutação sítio-dirigida da sequência de rhVEGF165. As sequências foram clonadas no vetor de clonagem pGEM®-T Easy, sendo em seguida subclonadas no vetor pLV-eGFP, um vetor plasmidial de transferência lentiviral, que permite a expressão de transgenes em células de mamíferos e, também, da proteína repórter eGFP. Células humanas HEK293 em cultura aderente foram independentemente cotransfectadas com cada uma das construções geradas (pLV-rhVEGF165, pLV-rhVEGF165b e pLV-rhVEGFl21) juntamente com o vetor pTK-Hyg na proporção de 40:1 (m/m), viabilizando a seleção dos transfectantes com o antibiótico higromicina B, além da detecção de eGFP. Os clones celulares superprodutores das proteínas de interesse foram avaliados quanto à cinética de expressão em meio carente de soro e adaptados para a cultura em suspensão estática na presença de meio na ausência de componentes derivados de animais, demostrando a capacidade de expressão das isoformas rhVEGFs nestas condições de cultivo. Para o nosso conhecimento, este é o primeiro trabalho a descrever a expressão de isoformas de VEGF-A em células HEK293 mantidas em suspensão. As isoformas rhVEGF165 e rhVEGF165b foram purificadas por cromatografia de afinidade a heparina, a partir do meio condicionado pelos clones superprodutores gerados. Ensaios in vitro, utilizando o AngioPhaseTM Kit, e in vivo, através do ensaio da membrana corioalantoide em embriões de galinha (CAM Assay), ambos próprios para avaliação da atividade pró- e antiangiogênica de diferentes compostos, demonstraram que a isoforma rhVEGF165 possui atividade biológica, enquanto a isoforma rhVEGF165b não apresentou a atividade esperada (inibição da angiogênese). Estas isoformas foram testadas em modelo murino de engenharia tecidual do intestino curto, com indícios de que poderiam contribuir para o uso terapêutico neste contexto. A purificação da isoforma rhVEGF121, bem como as análises estruturais das proteínas produzidas, estão em processo de otimização. / The first blood vessels of the vertebrate embryo are formed de novo from mesoderm-derived cells and give rise to lymph vessels in a process termed vasculogenesis. In the adult, new blood vessels are formed mainly through angiogenesis (or lymphangiogenesis) from the pre-existing vasculature. In healthy individuals, the vascular architecture is fairly static, and both the excess and the insufficiency of vessels comprise a pathological angiogenic state, to which is credited the onset and/or progression of several diseases such as cancer, age-related macular degeneration, limb ischemia, and many others. Therefore, locally controlling the blood vessel density becomes interesting for the treatment of pathological conditions aiming at prognosis improvement and cure. Among the various known growth factors, the vascular endothelial growth factor, VEGF, stands out as the major regulator of the angiogenic process. This process is mediated through the action of pro- (VEGFxxx) and antiangiogenic (VEGFxxxb) isoforms, which are derived from the VEGF-A gene. Consequently, the proteins encoded by this gene are potential therapeutic targets. In this work, we set out to produce the recombinant protein isoforms rhVEGF165, rhVEGF165b, and rhVEGF121, which originate from the human VEGF-A gene, with the aim of generating biopharmaceuticals to be used for molecular therapy and tissue engineering. The rhVEGF165 and rhVEGF121 coding sequences were amplified from total cDNA sythesized from human lung total RNA. Conversely, the rhVEGF165b coding sequence was generated by site-directed mutagenesis of the rhVEGF165 sequence. The sequences were cloned into the pGEM®-T Easy cloning vector. These cDNAs were then subcloned into pLV-eGFP, a plasmid lentiviral transfer vector that allows for expression of transgenes and the eGFP reporter protein in mammalian cells. Human HEK293 cells cultivated under adherent conditions were independently co-transfected with each of the obtained constructs (pLV-rhVEGF165, pLV-rhVEGF165b, and pLV-rhVEGF121) and the pTK-Hyg vector at a proportion of 40:1 (m/m), enabling for the selection of transfectants with hygromycin B, apart from the detection of eGFP. The cell clones overexpressing the proteins of interest were evaluated for expression kinetics in serum-deprived conditioned media and adapted to static suspension culture in medium free of animal-derived components, demonstrating that expression of the protein isoforms was possible in these culture conditions. To the best of our knowledge, this is the first work that describes the expression of VEGF-A isoforms in HEK293 cells in suspension culture. The rhVEGF165 and rhVEGF165b isoforms were purified by affinity chromatography from media previously conditioned by the overexpressing cell clones. The biological activity of rhVEGF165 was demonstrated in vitro, by the AngioPhaseTM Kit assay, and in vivo with the CAM (chorioallantoic membrane) assay, both of which are suitable for evaluating the pro- and antiangiogenic activity of different compounds. The rhVEGF165b did not show the expected antiangiogenic activity. These isoforms were tested in a model of murine tissue-engineered small intestine, indicating a possible contribution to therapeutic use in this context. The purification of rhVEGF121, as well as the structural analysis of all three proteins, are in the process of being optimized.

La structuration des réseaux neuronaux est un processus fondamental qui assure le bon fonctionnement du cerveau. Afin de comprendre la formation et l’activité de ces réseaux, nous souhaitons développer une méthode qui permette de contrôler in vivo sous l’action de la lumière l'expression de gènes ciblés impliqués dans ce phénomène,à l’échelle d’une cellule neuronale individuelle. Pour ce faire, nous utilisons une réaction de photo-clivage permettant de libérer de façon contrôlée un inducteur d’expression de gène sous l’action de la lumière, à l’aide de groupements photo-labiles sensibles aux excitations bi-photoniques développés au laboratoire et favorables aux applications in vivo. Afin de photo-réguler l'expression des gènes in vivo et avec un contrôle spatiotemporel élevé, nous combinons le système d’expression de gène inductible par la tétracycline « Tet-on » à une variété de précurseurs photo-activables d’analogues de tétracycline que nous avons synthétisés. Ceci devrait nous permettre de disposer d’un système efficace pour l’expression in vivo d’un gène d’intérêt par excitation lumineuse,et plus précisément dans le but de photo-réguler le gène Kir2.1 impliqué dans la régulation de l’activité électrique des neurones. / The structural neural network’s is a fundamental process that ensures the proper functioning of the brain. To understand the formation and activity of these networks, we are developing a method which spatio-temporally controlled in vivo, the expression of targeted genes involved in this process at individual neuron cells scale by light. To achieve this in vivo tests, it is necessary to work with methods which are orthogonal to their cellular environment. Photochemical activation by photo-cleavage of an inert biological precursor offers a unique orthogonal way to attain this spatio-temporal control. Therefore, we have recently developed a new family of photoremovable group which are sensitive to two-photon (TP) excitation sensitive, in order to irradiate at favorable wave-lengths for in vivo applications. Moreover, to photo-regulate the expression of genes with high spatial and temporal resolution, we are combining the inducible gene expression system by tetracycline called « Tet-on » system to different photo-activable precursors of tetracycline analogs obtained by hemi-synthesis. All this, should allow us to get an effective system for the in vivo expression of a gene of interest by light excitation in order to photoactivate Kir2.1, a gene that cell autonomously silences the electrical activity of neurons in a subset of cells.

Recently HER3, member of the epidermal growth factor receptor family (EGFR), has been found to play a crucial role in the development of resistance towards inhibitors that are given to patients with HER1- and HER2-driven cancers. As HER3 is up-regulated or over-activated in several types of human cancers, it is of outmost importance that new innovative drugs target its oncologic activity. The Affibody® Molecule Z08698 inhibits the heregulin induced signalling of HER3 with high affinity (KD~50 pM). As the Affibody® Molecule is small, has high solubility and outstanding folding kinetics, an effective penetration of tumour tissue is suggested together with a rationalized manufacturing process. Further coupling to an albumin binding domain (ABD) expands the plasma half-life of the molecule, hence increasing the molecule's potential of serving as a therapeutic. A process development for production of Z08698-VDGS-ABD094 has been established, where the molecule is efficiently produced in the E. coli host strain BL21(DE3), through a T7 based expression system. Cultivations were performed with a fed-batch fermentation process and the conditions were further optimized in order to obtain highest expression, while avoiding undesirable modifications like gluconoylations. By employing Design of experiments in combination with multivariate data analysis, a production process resulting in ~3.5 g product/ l culture could be verified. Moreover, thermolysis was evaluated as a suitable method for cell disruption, enabling an easy and cost-effective manufacturing process of the ABD fused Affibody® Molecule.

Les complexes multi-protéiques jouent un rôle crucial dans les cellules vivantes en catalysant et servant d'intermédiaires entre pratiquement toutes les activités cellulaires essentielles. Cependant, un grand nombre de ces machines se trouvent en très faibles quantités dans les cellules en particulier en ce qui concernent les complexes eucaryotes. Ceci est réfractaire à leur extraction à grande échelle et empêche sévèrement l'élucidation de leur structure et fonction. Dans le but de rendre les complexes multi protéiques accessibles par la voie de production recombinante, le groupe Berger a mis au point un ensemble de systèmes d'expression sur mesure pour la surproduction de complexes multi protéiques dans différents organismes hôtes incluant E. coli, les cellules d'insectes et les cellules de mammifères. Ces systèmes et en particulier le système MultiBac baculovirus/cellules d'insecte ont d'ors et déjà grandement contribués à l'étude de l'assemblage structural et fonctionnel à l'échelle moléculaire et atomique de nombreux complexes multi protéiques importants. Cela inclut en particulier le facteur général humain de transcription TFIID, un complexe de ~1.5 MDa qui constitue le sujet de recherche du laboratoire Berger. Mes contributions dans le développement de la technologie pour la production et dans l'élucidation des complexes TFIID humains sont discutées en détails dans cette thèse. / Multiprotein complexes play a crucial role in living cells by catalyzing and mediating virtually all essential cellular activities. However, many of these essential machines exist in very low endogenous amount in cells, in particular for eukaryotic complexes. This is refractory to large-scale extraction from native source material, severely impeding the elucidation of their structure and function. In order to make multiprotein complexes accessible by means of recombinant production, the Berger laboratory has developed an array of advanced expression systems tailor-made for overproducing multiprotein complexes in various host organisms including E. coli, insect cells and mammalian cells. Those systems, in particular the MultiBac baculovirus/insect cell system have already greatly contributed to studying the structural and functional assemblies of numerous important multiprotein complexes in molecular and atomic detail. Notably, this includes also the human general transcription factor TFIID, a ~1.5 MDa complex, which is the research focus of the Berger laboratory. My contributions to the expression technology development and to the structural elucidation of human TFIID complexes are discussed in details in this thesis.

Os primeiros vasos sanguíneos do embrião de vertebrados, formados de novo a partir de células originadas da mesoderme, originam os vasos linfáticos em um processo denominado vasculogênese. Já no adulto, novos vasos são formados principalmente através da angiogênese (ou linfoangiogênese) a partir da vasculatura pré-existente. Em indivíduos saudáveis, a arquitetura vascular é relativamente estática, sendo que o excesso ou a insuficiência de vasos são comumente relacionados à angiogênese patológica, vinculada a diversas doenças, como câncer, degeneração macular relacionada à idade, isquemia de membros e muitas outras. Dessa forma, o controle local da densidade de vasos sanguíneos torna-se interessante para o tratamento de condições patológicas visando melhoria de prognóstico e cura. Dentre os diversos fatores de crescimento conhecidos, o fator de crescimento endotelial vascular, VEGF, destaca-se como o principal regulador do processo de angiogênese através de isoformas pró-angiogênicas (VEGFxxx) e antiangiogênicas (VEGFxxxb) do gene VEGF-A. Consequentemente, as proteínas codificadas por esse gene constituem um alvo com alto potencial terapêutico. No presente estudo, propusemos a produção das isoformas proteicas recombinantes rhVEGF165, rhVEGF165b e rhVEGF121, oriundas do gene VEGF-A humano, visando à geração de biofármacos que podem ser utilizados para terapia molecular e engenharia tecidual. As sequências codificadoras das isoformas rhVEGF165 e rhVEGF121 foram amplificadas a partir do cDNA total sintetizado de amostras de RNA total de pulmão humano, enquanto que a da isoforma rhVEGF165b foi gerada através da mutação sítio-dirigida da sequência de rhVEGF165. As sequências foram clonadas no vetor de clonagem pGEM®-T Easy, sendo em seguida subclonadas no vetor pLV-eGFP, um vetor plasmidial de transferência lentiviral, que permite a expressão de transgenes em células de mamíferos e, também, da proteína repórter eGFP. Células humanas HEK293 em cultura aderente foram independentemente cotransfectadas com cada uma das construções geradas (pLV-rhVEGF165, pLV-rhVEGF165b e pLV-rhVEGFl21) juntamente com o vetor pTK-Hyg na proporção de 40:1 (m/m), viabilizando a seleção dos transfectantes com o antibiótico higromicina B, além da detecção de eGFP. Os clones celulares superprodutores das proteínas de interesse foram avaliados quanto à cinética de expressão em meio carente de soro e adaptados para a cultura em suspensão estática na presença de meio na ausência de componentes derivados de animais, demostrando a capacidade de expressão das isoformas rhVEGFs nestas condições de cultivo. Para o nosso conhecimento, este é o primeiro trabalho a descrever a expressão de isoformas de VEGF-A em células HEK293 mantidas em suspensão. As isoformas rhVEGF165 e rhVEGF165b foram purificadas por cromatografia de afinidade a heparina, a partir do meio condicionado pelos clones superprodutores gerados. Ensaios in vitro, utilizando o AngioPhaseTM Kit, e in vivo, através do ensaio da membrana corioalantoide em embriões de galinha (CAM Assay), ambos próprios para avaliação da atividade pró- e antiangiogênica de diferentes compostos, demonstraram que a isoforma rhVEGF165 possui atividade biológica, enquanto a isoforma rhVEGF165b não apresentou a atividade esperada (inibição da angiogênese). Estas isoformas foram testadas em modelo murino de engenharia tecidual do intestino curto, com indícios de que poderiam contribuir para o uso terapêutico neste contexto. A purificação da isoforma rhVEGF121, bem como as análises estruturais das proteínas produzidas, estão em processo de otimização. / The first blood vessels of the vertebrate embryo are formed de novo from mesoderm-derived cells and give rise to lymph vessels in a process termed vasculogenesis. In the adult, new blood vessels are formed mainly through angiogenesis (or lymphangiogenesis) from the pre-existing vasculature. In healthy individuals, the vascular architecture is fairly static, and both the excess and the insufficiency of vessels comprise a pathological angiogenic state, to which is credited the onset and/or progression of several diseases such as cancer, age-related macular degeneration, limb ischemia, and many others. Therefore, locally controlling the blood vessel density becomes interesting for the treatment of pathological conditions aiming at prognosis improvement and cure. Among the various known growth factors, the vascular endothelial growth factor, VEGF, stands out as the major regulator of the angiogenic process. This process is mediated through the action of pro- (VEGFxxx) and antiangiogenic (VEGFxxxb) isoforms, which are derived from the VEGF-A gene. Consequently, the proteins encoded by this gene are potential therapeutic targets. In this work, we set out to produce the recombinant protein isoforms rhVEGF165, rhVEGF165b, and rhVEGF121, which originate from the human VEGF-A gene, with the aim of generating biopharmaceuticals to be used for molecular therapy and tissue engineering. The rhVEGF165 and rhVEGF121 coding sequences were amplified from total cDNA sythesized from human lung total RNA. Conversely, the rhVEGF165b coding sequence was generated by site-directed mutagenesis of the rhVEGF165 sequence. The sequences were cloned into the pGEM®-T Easy cloning vector. These cDNAs were then subcloned into pLV-eGFP, a plasmid lentiviral transfer vector that allows for expression of transgenes and the eGFP reporter protein in mammalian cells. Human HEK293 cells cultivated under adherent conditions were independently co-transfected with each of the obtained constructs (pLV-rhVEGF165, pLV-rhVEGF165b, and pLV-rhVEGF121) and the pTK-Hyg vector at a proportion of 40:1 (m/m), enabling for the selection of transfectants with hygromycin B, apart from the detection of eGFP. The cell clones overexpressing the proteins of interest were evaluated for expression kinetics in serum-deprived conditioned media and adapted to static suspension culture in medium free of animal-derived components, demonstrating that expression of the protein isoforms was possible in these culture conditions. To the best of our knowledge, this is the first work that describes the expression of VEGF-A isoforms in HEK293 cells in suspension culture. The rhVEGF165 and rhVEGF165b isoforms were purified by affinity chromatography from media previously conditioned by the overexpressing cell clones. The biological activity of rhVEGF165 was demonstrated in vitro, by the AngioPhaseTM Kit assay, and in vivo with the CAM (chorioallantoic membrane) assay, both of which are suitable for evaluating the pro- and antiangiogenic activity of different compounds. The rhVEGF165b did not show the expected antiangiogenic activity. These isoforms were tested in a model of murine tissue-engineered small intestine, indicating a possible contribution to therapeutic use in this context. The purification of rhVEGF121, as well as the structural analysis of all three proteins, are in the process of being optimized.

Submitted by (edna.saturno@ufrpe.br) on 2016-10-14T14:08:17Z No. of bitstreams: 1 Karin Florencio Lins de Paiva Fontes.pdf: 1183202 bytes, checksum: cd071de0a1543bbb031923846a82c239 (MD5) / Made available in DSpace on 2016-10-14T14:08:17Z (GMT). No. of bitstreams: 1 Karin Florencio Lins de Paiva Fontes.pdf: 1183202 bytes, checksum: cd071de0a1543bbb031923846a82c239 (MD5) Previous issue date: 2013-01-19 / Equine Infectious Anemia (EIA), considered one of the most important viruses in horses in the world, is caused by a lentivirus of the Retroviridae family. It is a chronic infection without treatment, mainly prevalent in regions with hot and humid climate, favorable for transmission by blood-sucking insects. According to the Ministry of Agriculture, Livestock and Supply (MAPA), the restriction of transit and slaughter of infected animals are the strategies for the control of EIA in Brazil, which causes losses in equine breeding. The official diagnosis of the disease is carried out by detection of circulating antibodies by Agar Gel Immunodiffusion (AGID) and ELISA. The p26 protein from EIAV is highly conserved and used in most diagnostic tests, since it induces a strong humoral response. The aim of this work was the production of a p26 recombinant protein in Escherichia coli for use in serologic tests. The p26 gene sequence was optimized with respect to E. coli codon usage, in order to maximize protein production, and was added with a marker sequence of six histidine residues (6xHis-tag) for later protein detection and purification. The sequence was synthesized and cloned downstream of the gene of a maltose binding protein (MBP2*) on the pMAL-c4X expression vector. The E. coli gene induction was performed by Isopropyl β-D-1-thiogalactopyranoside and the resulting protein (MBP2*.p26mod) was detected by SDS-PAGE gel and Western blot with monoclonal anti-HIS. The MBP2*.p26mod was visualized as a 68.5 kDa band, the recombinant fusion protein was cleaved with factor Xa resulting in two bands of 42.5 and 26 KDa, corresponding to MBP2* and p26mod respectively. The MBP2*.p26mod purification was performed with affinity chromatography by nickel resin and yielded 78.12 mg/L of bacterial culture. The MBP2*.p26mod protein was intensely immunoreactive at AGID test where precipitation lines were observed only among the positive sera, including reference OIE serum, and the protein MBP2*.p26mod, showing high analytical sensitivity and specificity of the recombinant protein. / A Anemia Infecciosa Equina (AIE), considerada uma das viroses mais importantes em equinos no mundo, é causada por um lentivírus da família Retroviridae. É uma infecção crônica, sem tratamento, prevalente principalmente em regiões de clima quente e úmido, favorável à transmissão por insetos hematófagos. Segundo o Ministério da Agricultura e Pecuária e Abastecimento (MAPA), a restrição do trânsito e abate de animais infectados são as estratégias para o controle da AIE no Brasil, o que ocasiona perdas na equinocultura. O diagnóstico oficial da doença é realizado pela detecção de anticorpos circulantes através da imunodifusão em gel de Agar (IDGA) e de ELISA. A proteína p26 do vírus da AIE é altamente conservada e utilizada na maioria dos testes de diagnóstico, uma vez que induz uma forte resposta humoral. O objetivo com este trabalho foi a produção de uma proteína p26 recombinante em Escherichia coli para uso em testes diagnóstico sorológico. A sequência do gene p26 foi otimizada com relação aos códons preferenciais e ao conteúdo GC para uso em E. coli, a fim de maximizar a produção de proteínas, e foi adicionado à sequencia um marcador de seis resíduos de histidina (6xHis-tag) para posterior detecção e purificação protéica. A sequencia foi sintetizada e clonada a jusante do gene de uma proteína ligante de maltose (MBP2*) no vetor de expressão pMAL-c4X. A indução gênica da E. coli transformada foi realizada com isopropil β-D-tiogalactopiranosídeo e a proteína resultante (MBP2*.p26mod) foi detectada por SDS-PAGE em gel e Western blot com anticorpo monoclonal anti-HIS. A MBP2*.p26mod foi visualizada como uma banda de 68,5 kDa, a qual foi clivada com fator Xa resultando em duas bandas de 42,5 e 26 KDa, correspondentes à MBP2* e à p26mod respectivamente. A purificação MBP2*.p26mod foi realizada por cromatografia de afinidade com resina de níquel e foi obtido um rendimento de 78,12 mg/L de cultura bacteriana. A proteína MBP2*.p26mod foi intensamente imunoreativa no teste de IDGA, onde foram observadas linhas de precipitação únicas entre os soros positivos, inclusive o soro de referência OIE, e a proteína MBP2*.p26mod, demonstrando altas especificidade e sensibilidade analíticas da proteína recombinante.

Age stratified seroepidemiological studies play a crucial role in the design and assessment of vaccination strategies. An existing multiplex bead immunoassay for measles, mumps, rubella and varicella zoster virus antibodies together with a newly developed multiplex bead immunoassay for herpes simplex virus type 1 and type 2 antibodies were used to investigate the age-related seroepidemiology of these viruses in England during 2012.To develop the HSV-1 and HSV-2 antibody assay, attempts were made to produce full length of HSV-1 and HSV-2 glycoprotein G using a baculovirus vector expression system. While HSV-1 gG protein was produced, the proteins were extensively aggregated. Native glycoprotein G molecules undergo partial removal of HSV-1 signal sequence and HSV-1 short membrane anchor sequence during post translational modification. It is possible that such post translational modification is not performed when protein is processed in insect cell culture. Attempts to produce an HSV-2 glycoprotein G were not successful. It is possible that the high GC-content of HSV-2 glycoprotein G led to poor fidelity of copying the PCR amplification sequence. Commercially available truncated HSV-1 gG and HSV-2 gG were therefore used to develop a duplex microbead immunoassay for the simultaneous detection of specific HSV antibodies in human sera. The resultant assays performed with low sensitivity and specificity (HSV-1 of 89% and 66%, respectively and for HSV-2 of 79% and 85%, respectively) compared to the reference HerpeSelect ELISA.The MMRV multiplex bead immunoassay proved rapid, and required minimal sample volume to semi-quantify MMRV specific antibodies. The seroepidemiology of MMR results was compared with previous seroepidemiological studies performed in 1996 in England. The comparison showed an increase in the proportion of individuals who were positive for mumps and measles antibodies in the 2012 survey. The proportion of individuals positive for rubella was essentially unchanged. The increase in the proportion of individuals positive for mumps and measles antibodies in 2012 show the effectiveness of the change in MMR vaccination policy for England from 1996 onward. For VZV, the proportion of individuals who were positive for varicella antibodies between the 1996 and 2012 serological surveys were essentially unchanged. The comparison showed that most young children are susceptible to VZV. At this level of immunity, it can be expected that varicella will continue to produce epidemics of infection in the population, unless varicella vaccination is implemented as a part of routine childhood vaccination.